- Home
- TRNR vs ACXP Comparison
TRNR vs ACXP Comparison
Compare TRNR & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- ACXP
- Stock Information
- Founded
- TRNR 2017
- ACXP 2017
- Country
- TRNR United States
- ACXP United States
- Employees
- TRNR N/A
- ACXP N/A
- Industry
- TRNR Consumer Electronics/Appliances
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- ACXP Health Care
- Exchange
- TRNR Nasdaq
- ACXP Nasdaq
- Market Cap
- TRNR 5.9M
- ACXP 6.8M
- IPO Year
- TRNR 2023
- ACXP 2021
- Fundamental
- Price
- TRNR $2.45
- ACXP $4.45
- Analyst Decision
- TRNR
- ACXP Strong Buy
- Analyst Count
- TRNR 0
- ACXP 3
- Target Price
- TRNR N/A
- ACXP $143.67
- AVG Volume (30 Days)
- TRNR 196.5K
- ACXP 69.5K
- Earning Date
- TRNR 11-14-2025
- ACXP 11-12-2025
- Dividend Yield
- TRNR N/A
- ACXP N/A
- EPS Growth
- TRNR N/A
- ACXP N/A
- EPS
- TRNR N/A
- ACXP N/A
- Revenue
- TRNR $9,774,000.00
- ACXP N/A
- Revenue This Year
- TRNR $578.14
- ACXP N/A
- Revenue Next Year
- TRNR $130.65
- ACXP N/A
- P/E Ratio
- TRNR N/A
- ACXP N/A
- Revenue Growth
- TRNR 207.23
- ACXP N/A
- 52 Week Low
- TRNR $2.09
- ACXP $3.80
- 52 Week High
- TRNR $43.10
- ACXP $28.00
- Technical
- Relative Strength Index (RSI)
- TRNR 42.41
- ACXP 38.60
- Support Level
- TRNR $2.16
- ACXP $4.51
- Resistance Level
- TRNR $2.35
- ACXP $5.79
- Average True Range (ATR)
- TRNR 0.22
- ACXP 0.45
- MACD
- TRNR 0.00
- ACXP -0.11
- Stochastic Oscillator
- TRNR 35.21
- ACXP 11.11
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.